Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer

Julie Delvallée; Mathilde Cancel; Gilles Body; Sofiane Bendifallah; Cyril Touboul; Yohann Dabi; Pierre Collinet; Charles Coutant; Cherif Akladios; Vincent Lavoué; Pierre-Adrien Bolze; Cyrille Huchon; Alexandre Bricou; Geoffroy Canlorbe; Marcos Ballester; Xavier Carcopino; Camille Mimoun; Emile Darai; Lobna Ouldamer

doi:10.1016/j.jogoh.2021.102193

Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer

J Gynecol Obstet Hum Reprod. 2021 Dec;50(10):102193. doi: 10.1016/j.jogoh.2021.102193. Epub 2021 Jul 2.

Authors

Julie Delvallée¹, Mathilde Cancel², Gilles Body¹, Sofiane Bendifallah³, Cyril Touboul⁴, Yohann Dabi⁴, Pierre Collinet⁵, Charles Coutant⁶, Cherif Akladios⁷, Vincent Lavoué⁸, Pierre-Adrien Bolze⁹, Cyrille Huchon¹⁰, Alexandre Bricou¹¹, Geoffroy Canlorbe¹², Marcos Ballester¹³, Xavier Carcopino¹⁴, Camille Mimoun¹⁵, Emile Darai³, Lobna Ouldamer¹⁶

Affiliations

¹ Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069 Université François-Rabelais, Tours, France.
² Department of Oncology, Centre Hospitalier Universitaire de Tours, Tours, France.
³ Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
⁴ Department of Obstetrics and Gynaecology, Centre Hospitalier Intercommunal, Créteil, France.
⁵ Department of Gynaecologic surgery, Hôpital Jeanne de Flandre, CHRU LILLE, Rue Eugene avinée, 59037 lille cedex, France.
⁶ Department of Surgical Oncology, Georges-Francois Leclerc Cancer Centre, Dijon, France.
⁷ Department of Surgical Gynaecology, University Hospital of Strasbourg, Strasbourg, France.
⁸ Department of Gynaecology, CHU de Rennes, France. INSERM 1242, COSS, Rennes. Université de Rennes 1. France.
⁹ Department of Gynaecologic and Oncologic Surgery and Obstetrics, Centre Hospitalier Universitaire Lyon Sud, Hospices Civils de Lyon, Université Lyon 1, France.
¹⁰ Department of gynaecology, CHI Poissy-St-Germain, Université Versailles-Saint-Quentin en Yvelines, EA 7285 Risques cliniques et sécurité en santé des femmes, Université Versailles-Saint-Quentin en Yvelines, Versailles, France.
¹¹ Department of Gynaecology, Bobigny University, AP-HP, Hôpital Jean-Verdier, Bondy, France.
¹² Department of Gynaecologic and Breast Surgery and Oncology, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France.
¹³ Department of Gynaecologic and Breast Surgery, Groupe Hospitalier Diaconesses Croix Saint Simon, 125 rue d'Avron, 75020 Paris, France.
¹⁴ Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE UMR 7263, 13397, Marseille, France.
¹⁵ Department of Gynecology and Obstetrics, Lariboisiere Hospital, 750019 Paris, France.
¹⁶ Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069 Université François-Rabelais, Tours, France. Electronic address: l.ouldamer@chu-tours.fr.

PMID: 34224900
DOI: 10.1016/j.jogoh.2021.102193

Abstract

Background: The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients managed for stage I-IIa clear cell carcinoma, mucinous, low-grade serous and low-grade endometrioid ovarian cancer MATERIAL AND METHODS: Retrospective multicentre study of the research group FRANCOGYN between January 2001 and December 2018. All patients managed for stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer and for whom the presence of histological slides for the review of LVSI was available, were included. Patient's characteristics with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A cox analysis for OS and RFS analysis were performed in all population.

Results: Over the study period, 133 patients were included in the thirteen institutions. Among them, 12 patients had LVSI (9%). LVSI was an independent predictive factor for poorer Overall and recurrence free survivals. LVSI affected OS (p < 0.001) and RFS (p = 0.0007), CONCLUSION: The presence of LVSI in stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer has an impact on OS and RFS and should put them at high risk and consider the option of adjuvant chemotherapy.

Keywords: Lymphovascular space invasion; Ovarian cancer; Overall survival; Prognosis; Recurrence-free survival.

Publication types

Multicenter Study

MeSH terms

Adenocarcinoma, Clear Cell / drug therapy
Adenocarcinoma, Clear Cell / physiopathology
Adenocarcinoma, Mucinous / drug therapy
Adenocarcinoma, Mucinous / physiopathology
Adolescent
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant / methods*
Chemotherapy, Adjuvant / statistics & numerical data
Decision Support Techniques*
Endometrial Neoplasms / diagnosis
Endometrial Neoplasms / drug therapy*
Endometrial Neoplasms / physiopathology
Female
France / epidemiology
Humans
Middle Aged
Neoplasm Metastasis*
Neoplasm Staging / methods
Neoplasm Staging / statistics & numerical data
Ovarian Neoplasms / physiopathology*
Ovarian Neoplasms / therapy
Retrospective Studies